| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -29.0 | -21.0 |
| EPS (diluted, $ a share) | $-1.05 | $-0.99 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: NGNE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Neurogene Inc.: key numbers
- Share price
- $23.30Close, Nov 16
- Market cap
- $482M
- Shares outstanding
- 20.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Neurogene Inc.
All →Neurogene Financial Results
Neurogene Inc. reported third quarter 2026 financial results and provided a clinical update on its NGN-401 gene therapy program for Rett syndrome. The company expects topline data from its Embolden registrational trial in the second half of 2027 and confirmed its cash runway extends into the first quarter of 2029.
- Term
- Q3 2026
“During the third quarter, we continued to execute across all aspects of our NGN-401 program as we advance toward potential commercialization. With topline data from the Embolden registrational trial expected in the second half of 2027, we are progressing key BLA and commercial-readiness activities, including PPQ runs that we believe remain on track for completion this year.”
Rachel McMinn, Ph.D., Founder and Chief Executive Officer